LONDON (Reuters) - British pharmaceutical company AstraZeneca (L:AZN) named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of new oncology and immunology medicines.
AstraZeneca, Britain's second biggest drugmaker behind GSK (L:GSK), has pinned its future on cancer drugs, where it is vying with rivals such as Bristol-Myers Squibb (N:BMY), Merck & Co (N:MRK) and Roche (VX:ROG) in the hot area of immunotherapy treatments, which boost the immune system to fight tumours.
Bohen joins AstraZeneca from Genentech, a biotech company that was bought by Roche in 2009. He will report to Pascal Soriot, the chief executive who last year staved off a mega-merger approach from Pfizer (N:PFE).
"(Bohen's) impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients," Soriot said in a statement on Monday.